by Stacey Johnson | Aug 7, 2015
. First female scientists were #DistractinglySexy – and hilarious, I might add. (If this means nothing to you, I recommend you read this article for a good recap.) Now their female engineering friends and colleagues are also tackling sexism in STEM – science,...
by Mark Curtis | Jul 29, 2015
. Welcome to your Regenerative Medicine Deal Review for the month of June. It was an epic month in partnerships that saw multiple collaborations closely tying industry leaders together. Almost all public cell-based immunotherapy companies have formed partnerships with...
by Stacey Johnson | Jul 24, 2015
. You are probably ready for something more substantial from Right Turn after three weeks of light vacations posts. I have something that fits the bill. Greg Bonfiglio, Founder and Managing Partner of Proteus Venture Partners, was interviewed by PharmaTelevision in...
by David Kent | Jun 26, 2015
. I just sat through one of the simplest and most logical talks. Dr. Elly Tanaka, from Heidelberg, took the stage in the plenary session and described an incredible set of data that her lab has generated to understand the molecules involved in limb regeneration – a...
by Mark Curtis | Jun 24, 2015
. Welcome to your Update from the Clinic for the month of May. StemCells announced positive topline results from a Phase I/II study in spinal cord injury. Kite Pharma treated its first patient in a Phase I/II study investigating an anti-CD19 CAR T construct in...
by Mark Curtis | Jun 22, 2015
. Welcome to your deal review for the month of May. Juno Therapeutics was active, forming a strategic research collaboration with Fate Therapeutics and acquiring Stage Cell Therapeutics. Adaptimmune decided it would take advantage of the ongoing initial public...
Comments